华大基因(300676.SZ)发预减，半年度净利润5.8亿元–7.2亿元，同比下降33.7%-46.59%

智通财经2022-07-14

智通财经APP讯，华大基因(300676.SZ)披露2022年半年度业绩预告，公司预计半年度归属于上市公司股东的净利润5.8亿元–7.2亿元，同比下降33.70%-46.59%;扣除非经常性损益后的净利润5.15亿元–6.8亿元，同比下降33.95%-49.98%。公告显示，报告期内，公司基于新冠相关的业务收入较2021年同期较高基数有所下降。常规业务较2021年同期略有下降，其中，生育健康和感染...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

火星村长
2022-07-14
火星村长
这次不说拗口的有机增长了，变成全面下降了，和同期别的公司几倍几十倍的增长对比太鲜明了

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2251141488?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2022-07-14 19:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2251141488","market":"hk","top_or_hot":-1,"title":"华大基因(300676.SZ)发预减，半年度净利润5.8亿元–7.2亿元，同比下降33.7%-46.59%","media":"智通财经","content":"<div>\n<p>智通财经APP讯，华大基因(300676.SZ)披露2022年半年度业绩预告，公司预计半年度归属于上市公司股东的净利润5.8亿元–7.2亿元，同比下降33.70%-46.59%;扣除非经常性损益后的净利润5.15亿元–6.8亿元，同比下降33.95%-49.98%。公告显示，报告期内，公司基于新冠相关的业务收入较2021年同期较高基数有所下降。常规业务较2021年同期略有下降，其中，生育健康和感染...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/755738.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>华大基因(300676.SZ)发预减，半年度净利润5.8亿元–7.2亿元，同比下降33.7%-46.59%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n华大基因(300676.SZ)发预减，半年度净利润5.8亿元–7.2亿元，同比下降33.7%-46.59%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-07-14 19:26 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/755738.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，华大基因(300676.SZ)披露2022年半年度业绩预告，公司预计半年度归属于上市公司股东的净利润5.8亿元–7.2亿元，同比下降33.70%-46.59%;扣除非经常性损益后的净利润5.15亿元–6.8亿元，同比下降33.95%-49.98%。公告显示，报告期内，公司基于新冠相关的业务收入较2021年同期较高基数有所下降。常规业务较2021年同期略有下降，其中，生育健康和感染...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/755738.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"300676","symbol_name":"华大基因","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/755738.html","article_id":"2251141488","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2251141488","pubTimestamp":1657797986,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，华大基因 披露2022年半年度业绩预告，公司预计半年度归属于上市公司股东的净利润5.8亿元–7.2亿元，同比下降33.70%-46.59%;扣除非经常性损益后的净利润5.15亿元–6.8亿元，同比下降33.95%-49.98%。公告显示，报告期内，公司基于新冠相关的业务收入较2021年同期较高基数有所下降。报告期内，公司不断优化及推出新产品，持续推进海外业务的落地转化，为公司长期战略布局及业绩稳健增长提供重要支撑。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"300676":"华大基因"},"translate_title":"Huada Gene (300676. SZ) issued a pre-reduction, with a semi-annual net profit of 580 million yuan-720 million yuan, down 33.7%-46.59% year-on-year","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300676":1},"content_text":"智通财经APP讯，华大基因(300676.SZ)披露2022年半年度业绩预告，公司预计半年度归属于上市公司股东的净利润5.8亿元–7.2亿元，同比下降33.70%-46.59%;扣除非经常性损益后的净利润5.15亿元–6.8亿元，同比下降33.95%-49.98%。公告显示，报告期内，公司基于新冠相关的业务收入较2021年同期较高基数有所下降。常规业务较2021年同期略有下降，其中，生育健康和感染防控的业务收入较上年同期有所下降，肿瘤防控的业务收入较上年同期基本持平，多组学大数据与合成业务收入较上年同期实现稳健增长。报告期内，公司不断优化及推出新产品，持续推进海外业务的落地转化，为公司长期战略布局及业绩稳健增长提供重要支撑。在产品性能优化方面，公司升级了安馨可®新生儿及儿童基因检测、临床全基因组检测、胚胎植入前单基因病全基因组检测、白血病基因检测系列、PMseq®病原微生物高通量基因检测、高通量靶向代谢组学，发布百元级无创肝癌基因检测产品。在资质布局方面，CNV-seq(康孕®-染色体检测)、全自动PCR分析系统PMEasyLab及其配套的中枢神经系统感染病原体核酸多重检测试剂盒，细菌耐药基因多重检测和猴痘病毒检测试剂盒均获得了CE准入资质，α和β地中海贫血基因检测试剂盒(联合探针锚定聚合测序法)取得了国家药品监督管理局颁发的医疗器械注册证。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":688454371,"gmtCreate":1657806558698,"gmtModify":1704868362040,"author":{"id":"3585562039973035","authorId":"3585562039973035","name":"火星村长","avatar":"https://static.tigerbbs.com/d3fae97fd28d3ac4688309f16518e04d","vip":1,"crmLevel":2,"crmLevelSwitch":1},"htmlText":"这次不说拗口的有机增长了，变成全面下降了，和同期别的公司几倍几十倍的增长对比太鲜明了","listText":"这次不说拗口的有机增长了，变成全面下降了，和同期别的公司几倍几十倍的增长对比太鲜明了","text":"这次不说拗口的有机增长了，变成全面下降了，和同期别的公司几倍几十倍的增长对比太鲜明了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/688454371","repostId":2251141488,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2251141488"}